Heidelberg Pharma AG (LTS:0QW5) COGS-to-Revenue : 0.03 (As of Feb. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG COGS-to-Revenue?

Heidelberg Pharma AG's Cost of Goods Sold for the three months ended in Feb. 2025 was €0.04 Mil. Its Revenue for the three months ended in Feb. 2025 was €1.27 Mil.

Heidelberg Pharma AG's COGS to Revenue for the three months ended in Feb. 2025 was 0.03.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Heidelberg Pharma AG's Gross Margin % for the three months ended in Feb. 2025 was 96.54%.

Heidelberg Pharma AG COGS-to-Revenue Historical Data

The historical data trend for Heidelberg Pharma AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG COGS-to-Revenue Chart

Heidelberg Pharma AG Annual Data

Trend

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

COGS-to-Revenue

Get a 7-Day Free Trial

0.66

2.69

0.25

0.33

0.26

Heidelberg Pharma AG Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
COGS-to-Revenue	Get a 7-Day Free Trial															0.02	0.48	0.12	0.18	0.03

Heidelberg Pharma AG COGS-to-Revenue Calculation

Heidelberg Pharma AG's COGS to Revenue for the fiscal year that ended in Nov. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.78	/	6.849
	=	0.26

Heidelberg Pharma AG's COGS to Revenue for the quarter that ended in Feb. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.044	/	1.27
	=	0.03

Heidelberg Pharma AG (LTS:0QW5) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Heidelberg Pharma AG's Gross Margin % for the three months ended in Feb. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.044 / 1.27
	=	96.54 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Heidelberg Pharma AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines